Amarin Corp PLC (AMRN): Revenue
$213.65M
Year ended 2025-12-31
$186.23M
Trailing 12 months to 2026-06-30
-16.7%
3-year compound annual growth
-19.0%
5-year compound annual growth
+10.1%
10-year compound annual growth
| Period ended | Revenue | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $213.65M | -6.5% | 2026-03-02, From 2025-01-01 |
| 2024-12-31 | $228.61M | -25.5% | 2026-03-02, From 2024-01-01 |
| 2023-12-31 | $306.91M | -16.9% | 2026-03-02, From 2023-01-01 |
| 2022-12-31 | $369.19M | -36.7% | 2025-03-12, From 2022-01-01 |
| 2021-12-31 | $583.19M | -5.0% | 2024-02-29, From 2021-01-01 |
| 2020-12-31 | $614.06M | +42.9% | 2023-03-01, From 2020-01-01 |
| 2019-12-31 | $429.75M | +87.5% | 2022-03-01, From 2019-01-01 |
| 2018-12-31 | $229.21M | +26.6% | 2021-02-25, From 2018-01-01 |
| 2017-12-31 | $181.10M | +39.2% | 2020-02-25, From 2017-01-01 |
| 2016-12-31 | $130.08M | +59.1% | 2019-02-27, From 2016-01-01 |
| 2015-12-31 | $81.76M | +50.8% | 2018-02-27, From 2015-01-01 |
| 2014-12-31 | $54.20M | +105.7% | 2017-03-01, From 2014-01-01 |
| 2013-12-31 | $26.35M | n/a | 2015-03-03, From 2013-01-01 |
Revenue at similar companies
| Company | Year ended | Revenue | Change YoY |
|---|---|---|---|
| Amarin Corp PLC (AMRN) | 2025-12-31 | $213.65M | -6.5% |
| Vanda Pharmaceuticals Inc. (VNDA) | 2025-12-31 | $216.10M | +8.7% |
| IDEAYA Biosciences, Inc. (IDYA) | 2025-12-31 | $218.71M | n/m |
| Puma Biotechnology, Inc. (PBYI) | 2025-12-31 | $228.37M | -0.9% |
| Anaptysbio, Inc (ANAB) | 2025-12-31 | $234.60M | +157.0% |
| Akebia Therapeutics, Inc. (AKBA) | 2025-12-31 | $236.20M | +47.5% |
| Rhythm Pharmaceuticals, Inc. (RYTM) | 2025-12-31 | $189.76M | +45.8% |
| Keros Therapeutics, Inc. (KROS) | 2025-12-31 | $244.06M | n/m |
| Maravai Lifesciences Holdings, Inc. (MRVI) | 2025-12-31 | $185.74M | -28.3% |
Compare AMRN, VNDA, IDYA, PBYI side by side · Screen every company in Pharmaceutical Preparations ↗